CA2238004A1 - Procede diagnostique de differentiation selective fonde sur des bases de donnees etendues - Google Patents
Procede diagnostique de differentiation selective fonde sur des bases de donnees etendues Download PDFInfo
- Publication number
- CA2238004A1 CA2238004A1 CA002238004A CA2238004A CA2238004A1 CA 2238004 A1 CA2238004 A1 CA 2238004A1 CA 002238004 A CA002238004 A CA 002238004A CA 2238004 A CA2238004 A CA 2238004A CA 2238004 A1 CA2238004 A1 CA 2238004A1
- Authority
- CA
- Canada
- Prior art keywords
- data
- analysis
- neural network
- disorders
- computer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002405 diagnostic procedure Methods 0.000 title claims description 6
- 238000004458 analytical method Methods 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 46
- 238000013528 artificial neural network Methods 0.000 claims abstract description 43
- 239000011159 matrix material Substances 0.000 claims abstract description 40
- 230000008569 process Effects 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 22
- 238000012549 training Methods 0.000 claims abstract description 14
- 238000012360 testing method Methods 0.000 claims abstract description 13
- 210000002569 neuron Anatomy 0.000 claims abstract description 9
- 238000012512 characterization method Methods 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 7
- 238000011156 evaluation Methods 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 238000005481 NMR spectroscopy Methods 0.000 claims description 3
- 238000001479 atomic absorption spectroscopy Methods 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000000840 electrochemical analysis Methods 0.000 claims description 2
- 238000000921 elemental analysis Methods 0.000 claims description 2
- 238000004868 gas analysis Methods 0.000 claims description 2
- 238000004817 gas chromatography Methods 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 238000000495 ion-selective potentiometry Methods 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 238000012552 review Methods 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 claims 1
- 238000012546 transfer Methods 0.000 abstract description 13
- 208000035475 disorder Diseases 0.000 description 44
- 238000003556 assay Methods 0.000 description 43
- 239000012491 analyte Substances 0.000 description 34
- 230000006870 function Effects 0.000 description 29
- 239000000376 reactant Substances 0.000 description 28
- 239000013598 vector Substances 0.000 description 26
- 239000000523 sample Substances 0.000 description 24
- 239000000562 conjugate Substances 0.000 description 23
- 230000009870 specific binding Effects 0.000 description 16
- 238000009739 binding Methods 0.000 description 15
- 239000007790 solid phase Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000002820 assay format Methods 0.000 description 10
- 239000007795 chemical reaction product Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- -1 Acryl Chemical group 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910052797 bismuth Inorganic materials 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000004205 output neuron Anatomy 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000001778 Coronary Occlusion Diseases 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 210000002364 input neuron Anatomy 0.000 description 2
- 238000004969 ion scattering spectroscopy Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 229910001312 Amalgam (dentistry) Inorganic materials 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102100034784 Protein TANC2 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000448 dental amalgam Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000000918 plasma mass spectrometry Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical class C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/559,032 | 1995-11-15 | ||
| US08/559,032 US5687716A (en) | 1995-11-15 | 1995-11-15 | Selective differentiating diagnostic process based on broad data bases |
| PCT/US1996/018254 WO1997017891A1 (fr) | 1995-11-15 | 1996-11-15 | Procede diagnostique de differentiation selective fonde sur des bases de donnees etendues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2238004A1 true CA2238004A1 (fr) | 1997-05-22 |
Family
ID=29406081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002238004A Abandoned CA2238004A1 (fr) | 1995-11-15 | 1996-11-15 | Procede diagnostique de differentiation selective fonde sur des bases de donnees etendues |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2238004A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107437414A (zh) * | 2017-07-17 | 2017-12-05 | 镇江市高等专科学校 | 基于嵌入式gpu系统的并行化游客识别方法 |
| WO2021022365A1 (fr) * | 2019-08-02 | 2021-02-11 | Intellijoint Surgical Inc. | Systèmes et procédés pour collaborer, pour entraîner un système expert et pour fournir un système expert |
-
1996
- 1996-11-15 CA CA002238004A patent/CA2238004A1/fr not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107437414A (zh) * | 2017-07-17 | 2017-12-05 | 镇江市高等专科学校 | 基于嵌入式gpu系统的并行化游客识别方法 |
| WO2021022365A1 (fr) * | 2019-08-02 | 2021-02-11 | Intellijoint Surgical Inc. | Systèmes et procédés pour collaborer, pour entraîner un système expert et pour fournir un système expert |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5687716A (en) | Selective differentiating diagnostic process based on broad data bases | |
| Mayeux | Biomarkers: potential uses and limitations | |
| Zhang et al. | Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma | |
| Rothman et al. | Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. | |
| CN102713620B (zh) | 结合内外校准法的分析物定量多重微阵列 | |
| CN101479599A (zh) | 使用生物标记鉴别疾病状态的方法和设备 | |
| CN101903777A (zh) | 用于诊断和监测精神疾病的方法和生物标志物 | |
| Kouri et al. | Towards European urinalysis guidelines: introduction of a project under European Confederation of Laboratory Medicine | |
| MX2008012135A (es) | Tecnica de identificacion genetica de apolipoproteina. | |
| WO2007133586A2 (fr) | Systèmes et procédés destinés à développer des tests diagnostiques sur la base d'informations de biomarqueurs provenant d'ensembles d'échantillons cliniques existants | |
| AU659563B2 (en) | Method for the analysis of a component of a medical sample | |
| US5983211A (en) | Method and apparatus for the diagnosis of colorectal cancer | |
| Petersen et al. | Evaluation of systematic and random factors in measurements of fasting plasma glucose as the basis for analytical quality specifications in the diagnosis of diabetes. 3. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus | |
| Sasse | Objective evaluation of data in screening for disease | |
| JP3823162B2 (ja) | 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム | |
| Bernardi et al. | Requirements for improving quality in the measurement of bone markers | |
| CA2238004A1 (fr) | Procede diagnostique de differentiation selective fonde sur des bases de donnees etendues | |
| Listgarten et al. | Practical proteomic biomarker discovery: taking a step back to leap forward | |
| US20050079099A1 (en) | Generation of biochemical images and methods of use | |
| Berg et al. | Guidelines for evaluation of reagent strips. Exemplified by analysis of urine albumin and glucose concentration using visually read reagent strips: Ifcc Document | |
| Kinoshita et al. | Potential applications and limitations of proteomics in the study of neurological disease | |
| Wiener et al. | The use of knowledge-based information systems for interpreting specialized clinical chemistry analyses–experience from erythrocyte enzymes and metabolites | |
| Copeland et al. | The medical heritage concept: a model for assuring comparable laboratory results in long-term longitudinal studies | |
| Ruzzenente et al. | Elements of Metrology | |
| Ou et al. | Conjugated bilirubin versus direct bilirubin in neonates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |